Strengthening the earnings base through the continuous launch of original new products
First written in FY2016. 24 of 33 entries say "Restated". Latest entry: FY2026.
24 other companies' latest entry also says "Advanced".
- FY2026AdvancedAnnual report
「Against this operating backdrop, we began sales of BC・ROBO-9000RFID, the flagship model of our blood collection tube preparation equipment, and promoted proposals for solutions that improve the efficiency of testing operations, with this model at their core.」
The company reported the specific launch of a new product, the BC・ROBO-9000RFID flagship model of its blood collection tube preparation equipment. - 2026-05-26AdvancedResults presentation
「New product development, targeting the healthcare solutions and medical solutions fields」
The new product development policy specifies healthcare solutions and medical solutions as the target fields and presents a product roadmap and plans to launch new models. - FY2026-H1RestatedAnnual report
「R&D expenses for the cumulative interim accounting period were ¥209.553 million. There were also no significant changes in the status of the company's R&D activities during the cumulative interim accounting period.」
R&D expenses were ¥209.553 million, but the company stated that there were no significant changes in the status of research and development activities. No new milestones, such as completion or launch of a new product, were provided. - FY2025ReframedAnnual report
「The average development period for R&D projects is generally set at 2 to 5 years, taking into account market needs, technical hurdles and the R&D activities of other companies.」
The stated basic development period for R&D projects was expanded from 2 years to 2 to 5 years, broadening the assumed range of development periods. Total R&D expenses also increased to ¥690.523 million. - FY2025-H1RestatedAnnual report
「R&D expenses for the cumulative interim accounting period were ¥332.526 million. There were also no significant changes in the status of the company's R&D activities during the cumulative interim accounting period.」
The company recorded R&D expenses of ¥332.526 million, but stated that there were no significant changes in the status of research and development activities. No new milestones, such as completion or launch of a new product, were provided. - FY2024RestatedAnnual report
「The Company will continue to launch new products and further strengthen its earnings base by developing original new products with new value, cultivating new markets and actively investing management resources.」
The company has reaffirmed its policy of investing in the development of original new products, cultivation of new markets and continued product launches. R&D expenses were ¥404.027 million for blood collection tube preparation equipment and associated systems and ¥112.223 million for specimen testing equipment, for a total of ¥516.250 million, but no new product launch completion was reported. - FY2024-Q2RestatedAnnual report
「Against this operating backdrop, we further strengthened R&D activities related to our core blood collection tube preparation equipment and associated systems, worked to enhance the solutions we can provide, expanded sales of compact, high-performance new specimen testing equipment, and continued efforts to ensure a stable supply of consumables and other products.」
The company continues to strengthen R&D for blood collection tube preparation equipment and associated systems, expand sales of compact, high-performance new specimen testing equipment, and ensure a stable supply of consumables. No milestones such as completion of a new product launch were provided. - FY2024-Q1RestatedAnnual report
「Against this operating backdrop, we further strengthened R&D activities related to our core blood collection tube preparation equipment and associated systems, worked to enhance the solutions we can provide, expanded sales of compact, high-performance new specimen testing equipment, and continued efforts to ensure a stable supply of consumables and other products.」
The company continues to strengthen R&D for blood collection tube preparation equipment and associated systems and expand sales of compact, high-performance new specimen testing equipment. No new milestones that can be specifically identified, such as completion of a product launch, were provided. - FY2023AdvancedAnnual report
「During the fiscal year, we launched the new GASTAT-pro blood gas analyser. We will continue to expand our sales channels and promptly advance development of integrated blood gas electrodes and other products offering greater ease of use and accuracy.」
The company launched the new GASTAT-pro blood gas analyser, for which it had planned an early launch in the previous fiscal year. Development of integrated blood gas electrodes and other products, as well as expansion of sales channels, remain ongoing priorities. - FY2023-Q3RestatedAnnual report
「Total R&D expenses for the cumulative third quarter were ¥237.778 million. There were also no significant changes in the status of the company's R&D activities during the cumulative third quarter.」
The company recorded R&D expenses of ¥237.778 million, but stated that there were no significant changes in the status of research and development activities. No new milestones, such as completion or launch of a new product, were provided. - FY2023-Q2RestatedAnnual report
「R&D expenses for the cumulative second quarter were ¥160.608 million. There were also no significant changes in the status of the company's R&D activities during the cumulative second quarter.」
The company recorded R&D expenses of ¥160.608 million, but stated that there were no significant changes in the status of research and development activities. No new milestones, such as completion or launch of a new product, were provided. - FY2023-Q1RestatedAnnual report
「Total R&D expenses for the cumulative first quarter were ¥89.370 million. There were also no significant changes in the status of the company's R&D activities during the cumulative first quarter.」
R&D expenses were ¥89.370 million, and it is stated that there were no significant changes in the status of research and development activities. No new milestones were provided for new product development or continued product launches. - FY2022Development of specific new product plansAnnual report
「In 2022, we will seek the early launch of the new GASTAT-pro blood gas analyser and further expand our sales channels. We will also promptly advance development of integrated blood gas electrodes and other products offering greater ease of use and accuracy.」
The company specifically identified the early launch of the new GASTAT-pro blood gas analyser and development of integrated blood gas electrodes. This was described as the formulation of specific plans, rather than completion of a launch. - FY2022-Q2RestatedAnnual report
「R&D expenses for the cumulative second quarter were ¥187.104 million. There were also no significant changes in the status of the company's R&D activities during the cumulative second quarter.」
It is stated that there have been no significant changes in research and development activities, and the policy of continuously developing new products has been maintained. R&D expenses were ¥187.104 million. - FY2022-Q1RestatedAnnual report
「Total R&D expenses for the cumulative first quarter were ¥77.347 million. There were also no significant changes in the status of the company's R&D activities during the cumulative first quarter.」
It is stated that there have been no significant changes in research and development activities, and the policy of developing and continuously launching original new products has been maintained. R&D expenses were ¥77.347 million. - FY2021RestatedAnnual report
「The Company will continue to launch new products and further strengthen its earnings base by developing original new products with new value, cultivating new markets and actively investing management resources.」
The company has reaffirmed its policy of investing in the development of original new products, cultivation of new markets and continued product launches. R&D expenses were ¥433.255 million, and no specific milestones for completing or launching new products are provided. - FY2021-Q3RestatedAnnual report
「Total R&D expenses for the nine-month period were ¥284.032 million. There were no material changes in the status of the Company's R&D activities during the nine-month period.」
It is stated that there have been no significant changes in research and development activities, and the policy of developing and continuously launching original new products has been maintained. R&D expenses were ¥284.032 million. - FY2021-Q1RestatedAnnual report
「Total R&D expenses for the three-month period were ¥94.315 million. There were no material changes in the status of the Company's R&D activities during the three-month period.」
The Company states that there were no material changes in its R&D activities, and its policy of developing and continually launching original new products remains in place. R&D expenses were ¥94.315 million. - FY2020RestatedAnnual report
「The Company will continue to launch new products and further strengthen its earnings base by developing original new products with new value, cultivating new markets and actively investing management resources. During the fiscal year, the Company recorded R&D expenses of ¥410.135 million in the blood collection tube preparation system field and ¥266.139 million in the specimen testing system field, for a total of ¥676.275 million.」
The Company reconfirms its policy of continued new product launches and earnings base strengthening, and recorded R&D expenses of ¥676.275 million. No new specific milestone, such as new product completion or launch, is disclosed. - FY2020-Q2RestatedAnnual report
「R&D expenses for the six-month period were ¥258.749 million. There were no material changes in the status of the Company's R&D activities during the six-month period.」
The Company states that there were no material changes in its R&D activities, and its policy of continued new product development remains in place. R&D expenses were ¥258.749 million, with no milestone for new product completion or launch disclosed. - FY2020-Q1RestatedAnnual report
「Total R&D expenses for the three-month period were ¥101.695 million. There were no material changes in the status of the Company's R&D activities during the three-month period.」
The Company states that there were no material changes in its R&D activities, and its policy of developing and continually launching original new products remains in place. R&D expenses for the first quarter were ¥101.695 million, with no new milestone such as product completion or launch disclosed. - FY2019RestatedAnnual report
「The Company will continue to launch new products and further strengthen its earnings base by developing original new products with new value, cultivating new markets and actively investing management resources.」
The Company reiterates its policy of investing management resources in developing original new products, cultivating new markets and continuing product launches. No new launch milestone is disclosed. - FY2019-Q3RestatedAnnual report
「Amid this operating environment, the Company continued to secure replacement demand and identify new needs, including by beginning sales of Assist More, the latest system for its main blood collection tube preparation system.」
The Company continues to report the launch of Assist More sales, the capture of replacement demand and the identification of new needs. The launch itself had already been disclosed by the previous quarter, and no new product launch milestone is disclosed. - FY2019-Q1AdvancedAnnual report
「Amid this operating environment, the Company began sales of Assist More, the latest system in its blood collection operations support system, which assists blood collection operations by calling patients for collection and displaying patient information. In the specimen testing system field, the Company continued active sales efforts centered on the latest blood gas analyzer model, GASTAT-700Model.」
The Company began specific sales of the new Assist More system, the latest blood collection operations support system. Sales activities for GASTAT-700Model are also continuing. - FY2018RestatedAnnual report
「The Company is committing substantial human and other management resources to R&D of advanced technologies centered on specimen testing systems as an R&D-driven company. It will continue to reflect ideas collected and developed through joint research with universities and study groups involving external experts in product development, with the aim of launching new products that become new sources of revenue.」
The Company continues its policy of launching new products and strengthening its earnings base, citing joint research with universities, study groups with external experts and product development by project teams as the means of implementation. - FY2018-Q3RestatedAnnual report
「Amid this operating environment, the Company began sales at the start of the fiscal year of BC・ROBO-8001RFID, the latest model of its main blood collection tube preparation system, equipped with extensive functions to support smoother blood collection operations. In the specimen testing system field, the Company also continued to focus on expanding sales of the latest blood gas analyzer model, GASTAT-700Model.」
The Company continues to focus on the launch of BC・ROBO-8001RFID and the expansion of GASTAT-700Model sales. The launch of BC・ROBO-8001RFID had already been disclosed in the previous quarter, and no new milestone is disclosed. - FY2018-Q2RestatedAnnual report
「Revenue from specimen testing systems for the six-month period was ¥224.451 million, down 7.6% year on year. As a result of focusing on sales of the latest blood gas analyzer, GASTAT-700Model, overseas revenue increased 63.2% year on year to ¥42.220 million, while domestic revenue declined 16.0% to ¥182.230 million, as the scope of the product's sales rollout in Japan remained limited.」
The Company continues to focus on sales of GASTAT-700Model, but the scope of its sales rollout in Japan remains limited, and no new milestone for product sales is disclosed. - FY2018-Q1AdvancedAnnual report
「Amid this operating environment, the Company began sales of BC・ROBO-8001RFID, the latest model of its main blood collection tube preparation system, equipped with extensive functions to support smoother blood collection operations. In the specimen testing system field, the Company also continued to focus on expanding sales of GASTAT-700Model, launched in the previous fiscal year.」
The Company began sales of the latest blood collection tube preparation system, BC・ROBO-8001RFID, and continued expanding sales of GASTAT-700Model, which was launched in the previous fiscal year. The launch of sales of the new product represents specific progress. - FY2017AdvancedAnnual report
「Amid this operating environment, the Company worked to expand sales by offering a product lineup that meets the diverse needs of medical institutions, including by securing replacement demand for BC・ROBO-8000RFID, its main blood collection tube preparation system, and beginning sales of the GASTAT-700Model series of specimen testing systems, which feature enhanced remote maintenance functions.」
The launch of sales of the GASTAT-700Model series of specimen testing systems with enhanced remote maintenance functions was a specific product launch and sales milestone. - FY2017-Q3RestatedAnnual report
「Selling, general and administrative expenses increased to ¥1,878.730 million, up 12.4% year on year, mainly due to higher R&D expenses for developing a new blood collection tube preparation system with enhanced remote maintenance functions and a blood gas analyzer, resulting in」
Development of the new blood collection tube preparation system with enhanced remote maintenance functions and the blood gas analyzer is continuing. R&D expenses for the nine-month period totaled ¥458.073 million, with no new milestone such as product completion or launch disclosed. - FY2017-Q2RestatedAnnual report
「Selling, general and administrative expenses increased to ¥1,416.833 million, up 27.3% year on year, mainly due to higher R&D expenses for developing a new blood collection tube preparation system with enhanced remote maintenance functions and a blood gas analyzer, resulting in」
Development of the new blood collection tube preparation system with enhanced remote maintenance functions and the blood gas analyzer is continuing. No new milestone, such as product completion or launch, is disclosed. - FY2017-Q1RestatedAnnual report
「Research and development expenses increased to ¥603.169 million, up 11.8% year on year, mainly due to development costs for a new blood collection tube preparation system and a blood gas analyzer, resulting in」
Development of the new blood collection tube preparation system and blood gas analyzer is continuing, with R&D expenses for the quarter totaling ¥111.975 million. This represents continued new product development, with no specific milestone such as completion disclosed. - FY2016First statedAnnual report
「The Company will continue to launch new products and further strengthen its earnings base by developing original new products with new value, cultivating new markets and actively investing management resources.」
The Company presents new product development, new market cultivation, continued product launches and active investment of management resources as an integrated set of measures.